S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ACOR Acorda Therapeutics Inc

0.661

0.00 (0.00%)

Pre Market

Last Updated: 19:00:00

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Acorda Therapeutics Charts.

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Acorda Therapeutics Charts.

Acorda Therapeutics Inc News

Acorda Therapeutics Announces Delisting from Nasdaq
Monday 15 April 2024 (2 weeks ago) • Business Wire

Acorda Therapeutics Announces Nasdaq Delisting Notification
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Monday 1 April 2024 (4 weeks ago) • Business Wire

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
Monday 1 April 2024 (4 weeks ago) • Business Wire

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Monday 25 March 2024 (1 month ago) • Business Wire

Form 8-K - Current report
Thursday 11 January 2024 (4 months ago) • Edgar (US Regulatory)

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Thursday 11 January 2024 (4 months ago) • Business Wire

Form 8-K - Current report
Friday 1 December 2023 (5 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 13 November 2023 (6 months ago) • Edgar (US Regulatory)

Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Monday 13 November 2023 (6 months ago) • Business Wire

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
Monday 6 November 2023 (6 months ago) • Business Wire

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Monday 6 November 2023 (6 months ago) • Business Wire

More Acorda Therapeutics Inc News Articles

Yuenglings Ice Cream (PK)

Virexit Technologies (PK)

Elite Pharmaceuticals (QB)

BlueFire Equipment (PK)

FuelCell Energy

Branded Legacy (PK)

Canopus Biopharma (PK)

Global Developments (PK)

Globestar Therapeutics (PK)

Cann American (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions